BioNTech Clinical Trials

Clinical trials sponsored by BioNTech — phases, conditions and reported results. Data from ClinicalTrials.gov.

• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects Wi
  Phase 1/2 · Non-CNS Tumor · Terminated · Jul 2, 2026
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in
  Phase 3 · SARS-CoV-2 Infection, COVID-19 · Completed · May 28, 2026
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
  Phase 2/3 · SARS-CoV-2 Infection · Completed · Apr 28, 2026
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COV
  Phase 2/3 · SARS-CoV-2 Infection · Completed · Mar 25, 2026
• A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizuma
  Phase 2 · Advanced Melanoma · Completed · Jan 30, 2026
• Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
  Phase 1 · SARS-CoV-2 Infection · Completed · Jan 13, 2026
• A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients Wi
  Phase 2 · Melanoma Stage III · Completed · Dec 15, 2025
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate
  Phase 3 · Influenza · Completed · Dec 4, 2025
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVI
  Phase 3 · SARS-CoV-2 Infection · Completed · Nov 10, 2025
• Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in
  Phase 1/2 · Pancreatic Cancer · Terminated · Oct 31, 2025
• A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
  Phase 2/3 · SARS-CoV-2 Infection · Completed · Oct 1, 2025
• Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
  Phase 1 · Malaria · Completed · Sep 3, 2025
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates A
  Phase 2 · Influenza, Human · Completed · Jul 23, 2025
• BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
  Phase 1/2 · Solid Tumor · Terminated · Jul 2, 2025
• A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tu
  Phase 1/2 · Solid Tumor, Adult · Terminated · Apr 22, 2025

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials